Xeljanz

Pfizer's solo Xeljanz can't match AbbVie's Humira in big RA head-to-head miss

Questions swirl around Pfizer's I-O efforts, dealmaking future amid Q4 EPS miss

Rio Olympics end with big TV ad spending tallies, but pharma marketers finish in middle of pack

Hospira gives Pfizer big Q2 revenue boost as new brands Ibrance, Xeljanz offset Prevnar fall